bluuebunny/crossref_metadata_2025_split huggingface dataset:
Long‐term follow‐up of patients receiving salvage chemotherapy for intermediate and high grade non‐Hodgkin's lymphomas
Authors: Liang Raymond H. S. , Chiu Edmond K. W. , Chan T. K. , Todd David , Ng Ronald P. , Ho Faith F. C. , Loke S. L. 
Published: February 2007

AbstractThis is an analysis of the long‐term follow‐up data of 99 patients receiving HOAP‐Bleo, IMVP‐16 and PAC as salvage chemotherapy for refractory or relapsed intermediate or high grade non‐Hodgkin's lymphomas. Most of the patients received HOAP‐Bleo or PAC following failure of initial chemotherapy and IMVP‐16 was used mainly for HOAP‐Bleo failures. The longest follow‐up time of the surviving patients was 108 months. Twenty‐two and 29 per cent of the patients survived beyond 2 years following HOAP‐Bleo and PAC respectively. The treatment outcome following IMVP‐16 was worst with a 2‐year survival of only 5 per cent, as it was used mainly following HOAP‐Bleo failures. Although the prognosis of these refractory or relapsed cases are poor, salvage treatment is still worthwhile as a small proportion of these patients may have long‐lasting remissions and occasional patients may be cured. Newer approaches such as autologous bone marrow transplantation should be compared with current salvage chemotherapy regimens.
Ifosfamide and mitoxantrone (I‐M) in relapsed and refractory high grade non‐Hodgkin's lymphoma and Hodgkin's disease
Authors: Dovey G. J. , Child J. A. , Simmons A. V. , Barnard D. L. , Parapia L. , Morgan M. , Fletcher J. , Parker D. , Norfolk D. R. , Stone J. , Stuart N. S. A. , Tucker J. 
Published: February 2007

AbstractFifty‐five patients, initially diagnosed as having advanced high grade non‐Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) refractory to first‐line treatment or in relapse, were treated with ifosfamide 6 g/m2, infused over 48 h, followed by mitoxantrone 12 mg/m2. The regimen repeated at three‐weekly intervals. Of 32 patients with NHL evaluable for response, 10 (31 per cent) achieved complete remission and five partial remission, giving an overall response rate of 47 per cent. Two patients subsequently went on to bone marrow transplant (BMT)—one allogeneic and the other autologous. Of 17 patients with HD evaluable for response, six (35 per cent) achieved complete remission and six partial remission, giving an overall response rate of 71 per cent. Two of this group also went on to BMT (both autografts). The principal toxicity was neutropenia, though central nervous system changes were observed in 10 patients. Given the need to offer alternative treatment of patients in these categories, this combination (I‐M) is clearly of value in relapsed patients especially where therapeutic options are limited because of previous multi‐drug treatment.
Factor X‐activating procoagulant in normal and malignant breast tissue
Authors: El‐Baruni Khaled , Taylor Irving , Roath Stuart , Francis John L. 
Published: February 2007

AbstractFactor X‐activating activity (FXAA) was determined by a chromogenic assay in normal and malignant breast tissue. FXAA was found in all tissue (n = 38) irrespective of pathology, and the activity of normal tissue was similar to that of tumours. FXAA correlated with tissue hemoglobin in normal breast (p<0.02) but not in tumours. FXAA was markedly reduced by aluminium hydroxide, barium citrate, anti‐human factor VII, DFP, PMSF and phospholipase C, but was unaffected by iodoacetamide and mercuric chloride. It is concluded that FXAA is a serine protease with the properties of a tissue factor‐factor VII complex. FXAA occurs in normal and malignant breast tissue, although the ‘normal’ activity may be an artefact of the homogenization process.
Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone
Authors: Bell J. B. G. , Millar B. C. , Montes‐Borinaga A. , Joffe J. K. , Cunningham D. , Mansi J. , Treleaven J. , Viner C. , McElwain T. J. 
Published: February 2007

AbstractA study of 32 patients receiving cyclophosphamide (CY) and verapamil (VER) in addition to the drug combination vincristine, adriamycin and methyl prednisolone (VAMP) was made in which the clinical response and growth of clonogenic myeloma cells (MY‐CFUc) from bone marrow aspirates were compared. At presentation, MY‐CFUc were grown from 72 per cent (23/32) of the patients. After treatment with CY‐VAMP or VERCY‐VAMP, MY‐CFUc were grown from 25 per cent (8/32) of patients of whom only 50 per cent responded clinically. The overall clinical response rate for patients receiving CY‐VAMP and VERCY‐VAMP was 64 per cent (9/14) and 72 per cent (13/18) respectively of whom 14 per cent in each group achieved complete remission.There was no concomitant increase in normal tissue toxicity as measured by granulocyte–macrophage colony (GM‐CFUc) formation. Comparison of these data with our previous study of patients receiving VAMP alone, suggests that the addition of CY to the regimen may increase the tumour cell kill. Further clinical studies will determine whether there is a significant increase in the complete remission rate.
In vitro synergistic activity of PDN‐IFNα and NM + IFNα combinations on fresh bone‐marrow samples from multiple myeloma patients
Authors: Lepri Enrica , Barzi Anna , Menconi Emma , Portuesi Maria Giovanna , Liberati Marina 
Published: February 2007

AbstractThe differential staining cytotoxicity (DiSC) assay was used to evaluate the in vitro sensitivity of tumour and normal bone‐marrow cells from 21 multiple myeloma (MM) patients to antitumour agents methylprednisolone (PDN), nitrogen mustard (NM) and recombinant interferon α‐2b (IFNα) tested singly and in the combinations PDN+IFNα and NM+IFNα. Both the PDN‐IFNα and NM‐IFNα associations were more efficacious than any agents used singly in reducing the percentage of myeloma cell survival. However, whereas NM, alone and in combination with IFNα, provoked a severe reduction in normal bone‐marrow population, PDN and PDN+IFNα induced an increase percentage survival of normal bone‐marrow cells. These findings indicate that, at least in vitro, the PDN‐IFNα combination exerts a great antitumour effect which is not associated with a relevant cytotoxic activity on normal myeloid cells.
Anti‐BLA.36 monoclonal antibody shows reactivity with hodgkin's cells and B lymphocytes in frozen and paraffin‐embedded tissues
Authors: Croce David R. Della , Imam Ashraf , Brynes Russell K. , Nathwani Bharat N. , Taylor Clive R. 
Published: February 2007

AbstractA newly developed monoclonal antibody, anti‐BLA.36, raised against a Hodgkin cell line, was shown to have reactivity with Reed‐Sternberg cells and activated B lymphocytes and appears to be distinct from other antibodies which identify antigens of hematopoietic cells.Anti‐BLA.36 was evaluated in B5‐fixed paraffin‐embedded tissue from 16 cases of Hodgkin's disease of various types and 35 cases of non‐Hodgkin's lymphomas representative of the different major subtypes. The specificity of anti‐BLA.36 was compared with other antibodies that have been used to mark Hodgkin's cells and B lymphocytes: namely, L26, LN‐1, Leu‐M1 and Ber‐H2, as well as UCHL‐1, a pan‐T lymphocyte marker. In addition, a subset of the cases was evaluated using frozen tissue in order to validate the staining characteristics of anti‐BLA.36 as observed in fixed paraffin sections. Anti‐BLA.36 was found to react with Hodgkin's cells more consistently than the other antibodies used in this panel. The antibody reacted with an antigen on Reed‐Sternberg cells and their variants (Hodgkin's cells) in all four subtypes of Hodgkin's disease, and with a subset of reactive and malignant B lymphocytes, but not with T lymphocytes. It may, therefore, be useful in the evaluation of non‐Hodgkin's lymphomas.Finally, this is the first antibody raised to a Hodgkin's cell line which also consistently marks reactive and malignant B cells, but not T cells. The implications of this observation are discussed in relation to the cellular origin of the Reed‐Sternberg cell and the overall nature of Hodgkin's disease.
Ceftazidime and amikacin as empiric antibiotic therapy of febrile granulocytopenic patients with hematological malignancies. Report of 171 consecutive episodes
Authors: Todeschini G. , Veneri D. , Carlini S. , Pizzolo G. , Ambrosetti A. , Bonesi R. , Cassibba V. , Vinante F. , Meneghini V. , Perona G. 
Published: February 2007

AbstractOne hundred and seventy‐one consecutive febrile episodes occurring in 130 neutropenic adult patients with hematological malignancies (mainly acute leukemia) were empirically treated with a combination antibiotic therapy consisting of ceftazidime (100 mg/kg/day) + amikacin (15 mg/kg/day). Of these, 161 were evaluable.In the majority of episodes (75 per cent) documented infections were identified as a cause of fever. There were 73 bacteremias (34 Gram‐negative, 29 Gram‐positive, 10 polymicrobial). One third of patients had pneumonia. Cure without change of the initial regimen was achieved in 45/73 (62 per cent) bacteremic episodes and in 12/13 episodes of microbiologically documented infections without bacteremia. There were 35 clinically documented infections and 26 (74 per cent) of these were cured. Of the 40 patients presenting with possible infections 26 (65 per cent) were cured.Overall, cure without modification of the initial antibiotic combination was achieved in 109/161 episodes (68 per cent). In spite of the frequent occurrence of persistent neutropenia (82 per cent), the infectious mortality was low (8–6 per cent), and often due to superinfection. The deaths due to primary infections were 6/161 (3–7 per cent). Side effects were mild and rare.In our experience ceftazidime+amikacin was an effective and safe empirical regimen for this population of hematologic patients with persistent neutropenia and severe documented infections.
A phase II trial of promace‐cytabom in previously untreated non‐hodgkin's lymphoma of intermediate‐ or high‐grade histology
Authors: Rossi G. , Mariano M. R. , Arcangeli G. , Bonfanti V. , Capucci M. A. , Ferremi P. , Marpicati P. , Meriggi F. , Zaniboni A. , Izzi T. , Marini G. 
Published: February 2007

AbstractBetween November 1985 and June 1989 the aggressive combination chemotherapy programme ProMACE‐CytaBOM was used at a community‐based hospital as primary treatment for non‐Hodgkin's lymphoma (NHL) of intermediate or high‐grade histology in Ann‐Arbor stages IB‐IV. The 53 patients entering the study represented 90 per cent of all consecutive eligible patients with NHL diagnosed during the time period considered. Their median age was 54 years and median observation time was 36 months. Of 50 patients evaluable for response, 35 (70 per cent) achieved complete remission (CR), seven (14 per cent) partial remission, and five (10 per cent) were refractory. Treatment was given on an outpatient basis. Actually delivered drug doses ranged from 88 per cent to 97 per cent of the theoretical doses. Life‐threatening toxicity was experienced by four patients. Treatment was stopped in three cases (6 per cent) because of toxicity and there was one treatment‐related death. Actuarial 2‐year disease‐free survival of patients in CR was 73 per cent. Overall actuarial 3‐year survival and disease‐free survival were 67 per cent and 51 per cent respectively. High LDH level was a significant adverse prognostic factor both for achievement of CR (P < 0·005) and for survival (P < 0·0002). Age was of no prognostic importance. We conclude that ProMACE‐CytaBOM is an effective, easy to administer and well‐tolerated regimen for patients with aggressive NHL.
Polymorphism of the human HA‐RAS oncogene locus in chronic lymphocytic and chronic myelogenous leukemia
Authors: Knauf W. U. , Ho A. D. 
Published: February 2007

AbstractDNA from white blood cells from healthy controls demonstrates a restriction fragment length polymorphism (RFLP) of the Ha‐ras oncogene locus after cleavage with the restriction enzymes BamH I or MspI plus HpaII, representing frequent and rare alleles. We have studied the RFLP of 15 patients with B‐cell chronic lymphocytic (CLL) and of 16 patients with chronic myelogenous leukemia (CML). As in healthy controls the RFLP in the leukemic cells indicates the occurrence of frequent and rare Ha‐ras alleles. But rare alleles are not more frequent in the patients than in the healthy control group. The frequency of rare Ha‐ras alleles also does not differ between chronic lymphocytic and chronic myelogenous leukemia. While rare alleles of this oncogene locus occur in CML and CLL as frequently as in healthy controls, they do not reflect an inherent increased risk for chronic leukemia in man.
Phase II trial of ifosfamide and mesna in previously treated patients with non‐hodgkin's lymphoma: Cancer and leukemia group b study 8552
Authors: Case Delvyn C. , Anderson James , Ervin Thomas J. , Gottlieb Arlan 
Published: February 2007

AbstractIfosfamide (1·25 g/m2 intravenously/day × 5) with mesna (20 per cent of the ifosfamide dose × six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non‐Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29 per cent response rate (9/31) was observed (two CR and seven PR) with a median duration of response of 2·5 months. Myelosuppression was dose‐limiting. Hemorrhagic cystitis was observed in three patients (10 per cent). Nausea and vomiting was generally mild or moderate. One patient developed transient neurotoxic symptoms with confusion and disorientation. An additional patient developed an anaphylactic‐type reaction with shortness of breath and respiratory stridor during the fourth course of therapy. Ifosfamide, as a single agent, produces remissions of limited duration in non‐Hodgkin's lymphoma in patients in second or third relapse.
Toxicity and preliminary results with a new eight‐drug regimen (CEOP‐IMVP‐DEXA) in the treatment of aggressive lymphomas
Authors: Fridrik M. A. , Hausmaninger H. , Michlmayr G. , Haidinger R. , Seewann H. L. , Lehnert M. 
Published: February 2007

AbstractA combination of two non‐cross‐resistant regimens, CEOP and IMVP‐Dexa given every 4 weeks, three to six times according to response was tested in patients with untreated histological proven high and intermediate grade non‐Hodgkin's lymphoma.To date eight Austrian centres entered 37 patients in this multicentre trial. Data are available from 33 patients, three were excluded, two because of pretreatment, one because of wrong histology. Twenty‐five patients are evaluable for response, 21 had a complete and three a partial remission, two of them entered a complete remission after radiotherapy to residual disease, resulting in a complete remission rate of 92 per cent. Only one patient progressed during therapy. Until now three patients relapsed after achieving a remission. Observation time is 0±4–23±8 months, median 8±8 months.Toxicity was primarily hematologic with 53·3 per cent of patients having granulocyte nadirs below 0·5 × 109/L and 3·3 per cent below 0·1 × 109/L. Although 60 per cent of patients had infections, there was only one life‐threatening infection in an AIDS patient.CEOP‐IMVP‐Dexa can be safely given even in smaller hematologic centres and is able to achieve a high rate of complete responses in patients with high and intermediate grade malignant non‐Hodgkin's lymphomas.
Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: A phase II study
Authors: Tigaud Jean‐Dominique , Demolombe Sylvie , Bastion Yves , Bryon Paul‐André , Coiffier Bertrand 
Published: February 2007

AbstractA prospective phase II study was performed to evaluate efficacy and toxicity of continuous infusion ifosfamide plus etoposide combination in elderly patients (older than 70 years) with intermediate or high grade non Hodgkin's lymphoma. Chemotherapy was administered with mesna in order to avoid hemorrhagic cystitis. The 21 patients included were either unable to receive the usual front‐line chemotherapy given in our institution or relapsing after or not responding to conventional chemotherapy. Only one out of 97 courses of chemotherapy was followed by serious complication consisting in non‐lethal pneumonitis. Four out of seven previously untreated patients and five patients treated in first relapse achieved complete response (75 per cent). Out of nine refractory or previously multi‐treated patients, only one achieved complete response. We conclude that combination of continuous infusion ifosfamide plus etoposide deserves to be evaluated on a larger scale so that the optimum doses and schedule may be defined.
IMVP‐16 followed by high dose chemotherapy and autologous bone marrow transplantation as salvage treatment for malignant lymphoma
Authors: Huijgens P. C. , Ossenkoppele G. J. , Van Der Lelie J. , Thomas L. L. M. , Wijngaarden M. J. , Slaper C. M. 
Published: February 2007

AbstractThirty patients with high‐grade malignant lymphoma were treated with ifosfamide‐VP16213‐methotrexate (IMVP‐16) combination chemotherapy after failing to respond completely or after relapsing on CHOP‐like therapy. Responders to the salvage therapy subsequently were treated with ablative chemotherapy (BCNU. VP16213, Ara‐C and melphalan) and autografted. Of these 30 patients 11 were in relapse, 11 were partial responders and eight failed CHOP‐like therapy. There were eight complete remissions and 12 partial responses to IMVP‐16. These 20 patients were transplanted, together with one nonresponder. Ten of these 21 patients are disease‐free survivors 16 to 76 months (median 32) after autografting. There were three treatment‐related deaths: one before and two during the autografting procedure.Using one of the best salvage therapy combinations followed by high dose chemotherapy and autografting is feasible. The results of this study suggest that an appreciable number of patients may be cured by this procedure.
Ifosfamide in the treatment of high‐grade recurrent non‐hodgkin's lymphomas
Authors: Magrath Ian , Adde Melissa , Sandlund John , Jain Vinay 
Published: February 2007

AbstractWe report the results of two phase II trials of ifosfamide in very high risk patients with either partially responsive or recurrent non‐Hodgkin's lymphomas. In the first study, in which patients were extremely heavily pretreated (50 per cent had received a very intensive salvage regimen containing very high dose cyclophosphamide), there were two complete responses, two partial responses and one objective (minimal) response among 14 patients treated. Toxicity was acceptable even in this end‐stage patient group. We concluded that ifosfamide is an active agent even in patients with tumours resistant to cyclophosphamide. The second trial was a pilot study in 13 patients of a regimen incorporating VP16, ifosfamide/mesna, and high dose ara‐C (VIPA). There were four complete responses, five partial responses and two objective responses. Two patients died in complete remission from toxic complications, while a third, with a stably regressed mediastinal mass died after completion of the protocol. While very toxic, we considered that this regimen was highly effective, and have since incorporated a slightly less intensive combination of the same drugs into the primary therapy of high risk patients. Since the primary toxicity of the VIPA combination was myelosupression. the use of a modified protocol incorporating colony stimulating factors to ameliorate the side‐effects and possibly increase dose rate is worthy of further exploration in patients with recurrent B cell tumours.
Prolonged disease‐free survival in pediatric non‐hodgkin's lymphoma using ifosfamide‐containing combination chemotherapy
Authors: Gad‐El‐Mawla Nazli , Hamza M. R. , Abdel‐Hadi S. , El‐Tannir O. , Hussein M. H. , El‐Haddad A. , Adde Melissa , Magrath Ian 
Published: February 2007

AbstractPediatric non‐Hodgkin's lymphoma (NHL) constitutes 16 per cent of pediatric malignancies reported to the National Cancer Institute (NCI) in Cairo. The adopted treatment for these cases was, from 1982 to July 1985. a modified St Jude's regimen consisting of: vincristine, cyclophosphamide, adriamycin, prednisone and intrathecal methotrexate for the first 6 weeks for induction, followed by cranial irradiation for cranial prophylaxis. Patients in remission received maintenance therapy for 18 months. Of 32 patients complete remission (CR) was achieved in 24 patients (75 per cent); partial remission (PR) in one patient (3 per cent): five patients showed no response (15 per cent) while two patients died during the induction phase. At 60 + months follow‐up, 60 per cent of cases are still alive, disease‐free, and overall survival is 66 per cent. A new protocol was adopted in 1985, consisting of alternating cycles: A and B, for 4–8 cycles. Cycle A: cyclophosphamide. high dose ara‐C, adriamycin, and vincristine. Cycle B: ifosfamide, methotrexate, VP 16, with intrathecal methotrexate. The response in 39 cases is: CR in 31 cases (82 per cent); PR in four cases (10 per cent): no response in three cases (8 per cent). At 60+ months, the disease‐free survival is 60 per cent, and overall survival 80 per cent. This new protocol has the advantage of: short duration of therapy and so better patient compliance, no maintenance therapy or cranial irradiation with its sequelae in the future. Moreover, it has a better overall survival.
A comparative study of proliferation‐associated parameters in b‐cell non‐hodgkin lymphoma
Authors: Rehn Suzanne , Glimelius Bengt , Sundström Christer 
Published: February 2007

AbstractThe prognostic value of three proliferation‐associated parameters, the frequency of cells in S‐phase, mitotic index (MI) and serum deoxythymidine kinase levels (S‐TK), was examined in 106 primary cases of B‐cell non‐Hodgkin lymphomas (NHL), 76 ‘low grade’ NHL and 30 ‘high grade’ NHL and compared with morphology and clinical variables. All three proliferation factors displayed large differences in the mean values of the two groups ‘low grade’ and ‘high grade’ NHL, and all revealed significant prognostic information. In ‘low grade’ NHL, the information decreased with follow‐up time. A correlation (r=0·7) was noted between S‐phase values and MI but not between S‐TK and the two others. In the entire patient material and in the two prognostic groups defined by morphology, S‐TK gave the best prognostic information. MI gave better prognostic information than S‐phase values in the whole material and in ‘low grade’ NHL, whereas the reverse appeared to be true for ‘high grade’ NHL. In the multivariate analyses, no other parameter apart from S‐TK provided any further prognostic importance in the cases of ‘high grade’ NHL, whereas in that of ‘low grade’ NHL, MI, stage, age and histology had independent importance.